Xtalks — The Life Science Community™, Online webinar
2026-10-29
Weight-loss medications work only while patients keep taking them. The real goal is staying on medication long enough to achieve meaningful, functional weight loss and sustain it. This webinar explores why that's harder than it sounds: not for the clinical reasons often expected, but rather because of the beliefs and psychology, including the significance of volitional medication use in obesity, that predict who stays engaged and who drops off before seeing the long-term benefits. For pharma professionals supporting an obesity portfolio, that gap is an important challenge to address. Clinical trials show sustained weight reduction of 15–22% over 72 weeks, but real-world discontinuation can be up to 67% within 12 months. Side effects, cost and access explain only part of that drop-off. Most support programs have no validated way to identify behavioral risk before it impacts success. Psychological factors, such as confidence, doubt and treatment identity, are increasingly recognized as independent predictors of discontinuation. Underlying motivations and beliefs about treatment, whether rooted in appearance, day-to-day function or long-term health risk, differ from patient to patient. Left unaddressed, these differences can determine whether someone stays on treatment and reaches a functional, lasting outcome. Digital health technology can help keep people engaged and on track. The featured speakers will discuss findings from a novel study of 1,056 US adults using a GLP-1/GIP medication for weight management, evaluated using the SPUR behavioral framework alongside validated belief and mental-health measures. They'll introduce Kaitality™, Clinical ink's general wellness app, and show how connecting biometrics (weight, body composition and activity), sociometrics (social context and daily environment) and psychometrics (validated psychological drivers of adherence) can generate real-world evidence and support progress toward sustained functional quality weight loss goals. Register for this webinar to learn how a behavioral profile can help identify adherence risk, personalize patient support and support sustained functional weight loss.
|
|
|
Invited Speakers:
|
|
Christian Djurhuus, MD, PhD, EVP Disease Management, Chief Scientific Officer, Clinical ink Nicholas Alp, MD, PhD, FACC Chief Medical Officer, Clinical ink (Moderator) Bob DiLuzio, Senior Vice President, Disease Management, Clinical ink
|
|